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n the last two decades, intense research efforts
aiming to provide a better understanding of astroglial
cell function have revealed a number of previously
unsuspected roles for these neural cells, which were long
considered as relatively passive structural elements of
the brain. It has now become quite clear that a plethora
of cooperative metabolic processes and interdependen-
cies exist between astrocytes and neurons. As a result of
the growing appreciation of the role of astrocytes in both
the normal and diseased brain, the traditional neuron-
centric conception of the central nervous system (CNS)
has been increasingly challenged. 
Astrocytes are territorial cells: they extend several
processes with little overlap between adjacent cells,
forming highly organized anatomical domains
1-3 which
are interconnected into functional syncytia via abundant
gap junctions.
4 These astrocytic processes closely
ensheath synapses and express a wide range of receptors
for neurotransmitters, cytokines, and growth factors, as
well as various transporters and ion channels.
5-11 In addi-
tion, astrocytes project specialized astrocytic endfeet
which are in close contact with intraparenchymal blood
vessels, almost entirely covering their surface.
12,13
Together, these cytoarchitectural and phenotypical fea-
tures ideally position astrocytes to fulfill a pivotal role in
brain homeostasis, allowing them not only to sense their
surroundings but also to respond to—and consequently
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Astrocytes are the main neural cell type responsible for
the maintenance of brain homeostasis. They form highly
organized anatomical domains that are interconnected
into extensive networks. These features, along with the
expression of a wide array of receptors, transporters, and
ion channels, ideally position them to sense and dynam-
ically modulate neuronal activity. Astrocytes cooperate
with neurons on several levels, including neurotransmit-
ter trafficking and recycling, ion homeostasis, energy
metabolism, and defense against oxidative stress. The
critical dependence of neurons upon their constant sup-
port confers astrocytes with intrinsic neuroprotective
properties which are discussed here. Conversely, patho-
genic stimuli may disturb astrocytic function, thus com-
promising neuronal functionality and viability. Using
neuroinflammation, Alzheimer’s disease, and hepatic
encephalopathy as examples, we discuss how astrocytic
defense mechanisms may be overwhelmed in patholog-
ical conditions, contributing to disease progression. 
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astrocytes can respond to neurotransmitters with tran-
sient increases in their intracellular Ca
2+ levels, which can
travel through the astrocytic syncytium in a wavelike
fashion.
14,15These Ca
2+ signals can trigger the release of
neuroactive molecules from astrocytes (or gliotransmit-
ters), such as glutamate, D-serine, or adenosine triphos-
phate (ATP) which in turn modulate synaptic activity
and neuronal excitability (see ref 16 for review). This
process, for which the term “gliotransmission” has been
coined, marks the emergence of an exciting new notion
that information processing may not be a unique feature
of neurons. 
Remarkably, the phylogenetic evolution of the brain cor-
relates with a steady increase of the astrocyte-to-
neuron ratio—going from about 1/6 in nematodes to 1/3
in rodents, and reaching up to 1.65 astrocytes per neuron
in the human cortex.
3,17 Importantly, more than simply
outnumbering their rodent counterparts, human astro-
cytes are also strikingly more complex, both morpho-
logically and functionally. In comparison, human neo-
cortical astrocytes are 2.5 times larger, extend 10 times
more processes, and display unique microanatomical
features (Figure 1).
2 In addition, they generate more
robust intracellular Ca
2+ responses to neurotransmitter
receptor agonists and display a 4-fold increase in Ca
2+
wave velocity.
2 In light of these evolution-driven modi-
fications, it is tempting to hypothesize that the astrocytic
contribution to the overall neural network complexity
may in part provide the fine tuning necessary to take
information processing to a higher level of competence,
such as that seen in humans. At the very least, the evo-
lutionary pressure exerted on astrocytes highlights the
importance of this glial cell type in sustaining normal
brain function as the brain itself becomes more complex. 
A continuously growing body of evidence demonstrates
that astrocytes are essential sentinels and dynamic mod-
ulators of neuronal function. Considering the strong
metabolic cooperation that exists between these two cell
types, it is not surprising that alterations in astrocytic
function have been shown to have potentially cata-
strophic consequences for neurons. In the present review
we discuss the intrinsically protective role of astrocytes
in the normal brain, and examine how these defense
mechanisms may be overwhelmed in pathological con-
ditions, contributing to disease progression. 
Astrocytes in the normal brain: 
maintenance of extracellular homeostasis
Despite the fact that the brain has a very high metabolic
rate, neurons are by nature particularly sensitive to
minute changes in their microenvironment. In this con-
text, neuronal function and viability would rapidly be
compromised without effective mechanisms for the sup-
ply of metabolic substrates and—equally as important—
for the removal of waste products. In this respect, astro-
cytes play an essential role through a number of cellular
processes; some of the most important are outlined in
the following section. 
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Selected abbreviations and acronyms
A amyloid-beta
AD Alzheimer’s disease
GSH glutathione
MCT monocarboxylate transporter
ROS reactive oxygen species
Figure 1. Human astrocytes are more complex then their rodent coun-
terparts. Typical human (A) and mouse (B) protoplasmic astro-
cytes are shown at the same scale for comparison. Based on glial
fibrillary acidic protein (GFAP) immunostaining, human proto-
plasmic astrocytes are 2.5-fold larger and project 10 times more
main processes than mouse astrocytes. (GFAP, white. Scale bar,
20 µM).
Adapted from ref 2: Oberheim NA, Takano T, Han X, et al. Uniquely
hominid features of adult human astrocytes. J Neurosci. 2009;29:3276-
3287. Copyright © Society for Neuroscience 2009
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Astrocytic processes surrounding synaptic elements
express transporters for a variety of neurotransmitters
and neuromodulators including glutamate, γ-aminobu-
tyric acid (GABA), glycine, and histamine.
5-8These trans-
porters participate in the rapid removal of neurotrans-
mitters released into the synaptic cleft, which is essential
for the termination of synaptic transmission and main-
tenance of neuronal excitability. In the specific case of
glutamate, its uptake by astrocytes is also crucial in pro-
tecting neurons against glutamate-induced excitotoxic-
ity. Indeed, although glutamate is the primary excitatory
neurotransmitter in the brain, overstimulation of gluta-
mate receptors is highly toxic to neurons (reviewed in
detail by Sattler and Tymianski).
18While basal extracel-
lular glutamate levels are maintained in the low micro-
molar range, they increase dramatically during gluta-
matergic neurotransmission, reaching up to 1 mM for a
few milliseconds in the synaptic cleft.
19 This concentra-
tion of glutamate would cause extensive neuronal injury
in the absence of highly efficient mechanisms for its
removal at the synapse. This is primarily achieved by the
astrocyte-specific sodium-dependent high-affinity glu-
tamate transporters GLT-1 and GLAST (corresponding
to human EAAT2 and EAAT1, respectively) and to a
lesser extent by the neuronal glutamate transporters
EAAC1 (human EAAT3) and EAAT4.
7A number of in
vitro and in vivo studies demonstrate the primary impor-
tance of astrocytic glutamate uptake in preventing glu-
tamate-induced excitotoxicity.
20-23A good example is pro-
vided by the phenotypical changes displayed by
knockout mice for the various glutamate transporters.
Indeed, knockout mice for GLT-1, considered the main
astrocytic glutamate transporter, suffer lethal sponta-
neous seizures and selective hippocampal neuronal
degeneration,
24 whereas knockout mice for the neuronal
EAAC1 display no apparent neurodegeneration.
25
Interestingly, beta-lactam antibiotics have been shown
to upregulate the expression of GLT-1 and to prevent
neuronal loss both in vitro and in vivo in models involv-
ing excitotoxicity.
26This suggests that modulation of the
glutamate uptake capacity of astrocytes may be achiev-
able in vivo with classical pharmacological tools, thus
representing a promising therapeutic target for patholo-
gies involving excitotoxicity. 
Astrocytes also play a central role in the transfer of glu-
tamate back to neurons following its uptake at the
synapse. Failure to do so would result in the rapid deple-
tion of the glutamate pool in presynaptic neurons and
subsequent disruption of excitatory neurotransmission.
This transfer is achieved by the well-described gluta-
mate-glutamine cycle (Figure 2, pink box).
27,28 In short,
glutamate is converted to glutamine by the astrocyte-
specific enzyme glutamine synthetase (GS).
29 Glutamine
is then transferred to neurons in a process most likely
involving the amino acid transport systems N, L, and
ASC in astrocytes and system A in neurons.
27 Glutamine
is then converted back to glutamate via deamination by
phosphate-activated glutaminase which is enriched in
the neuronal compartment. The ammonia produced in
the process is thought to be shuttled back to astrocytes
following its incorporation into leucine and/or alanine.
27
It is important to note that glutamate can be metabo-
lized in a number of different pathways in astrocytes and
neurons, including oxidation in the tricarboxylic acid
(TCA) cycle.
28Astrocytes are responsible for the replen-
ishment of brain glutamate, as they are the only neural
cell type expressing pyruvate carboxylase, a key enzyme
in the main anaplerotic pathway in the brain, effectively
allowing them to synthesize glutamate from glucose.
30,31
This represents another level of cooperation between
astrocytes and neurons.
K
+ buffering
Apart from the release of neurotransmitters which have
to be rapidly removed from the synaptic cleft, neuronal
activity and the resulting propagation of action poten-
tials causes substantial local increases of extracellular
potassium ions (K
+) in the restricted extracellular space.
Without tight regulatory mechanisms, this could dra-
matically alter the neuronal membrane potential, lead-
ing to neuronal hyperexcitability and seriously compro-
mising CNS function.
32 Such a scenario is prevented by
the buffering of extracellular K
+ by glial cells
33,34 (Figure 2,
orange box). Indeed, astrocytes have a strongly negative
resting potential and express a number of potassium
channels, resulting in a high membrane permeability to
K
+.
35These features, in conjunction with the action of the
Na
+/K
+ ATPase, enable astrocytes to accumulate the
excess extracellular K
+,
36 which can then travel in the
astrocytic syncitium through gap junctions down its con-
centration gradient.
34,35 This allows for the spatial dis-
persion of K
+ from areas of high concentration to areas
of lower concentration where it can be extruded either
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Figure 2. Simplified representation of the main roles of astrocytes in brain homeostasis. Pink box: glutamate-glutamine cycle. Astrocytic excitatory amino
acid transporters (EAATs) are responsible for the uptake of a large fraction of glutamate at the synapse. Glutamate is converted into gluta-
mine by glutamine synthetase (GS) and shuttled back to neurons for glutamate resynthesis. Blue boxes: Lactate shuttle. Glutamate uptake by
astrocytes is accompanied by Na
+ entry which is counteracted by the action of the Na
+/K
+ ATPase. The resulting increase in ADP/ATP ratio trig-
gers anaerobic glucose utilization in astrocytes and glucose uptake from the circulation through the glucose transporter GLUT1. The lactate
produced is shuttled to neurons through monocarboxylate transporters (mainly MCT-1 in astrocytes and MCT-2 in neurons), where it can be
used as an energy substrate after its conversion to pyruvate. Yellow box: pH buffering. Abundant carbonic anhydrase (CA) in astrocytes
converts CO2 into H
+ and HCO3
-. Two HCO3
- are transported into the extracellular space along with one Na
+ via the Na
+-HCO3
- cotransporter
(NBC), thereby increasing the extracellular buffering power. Protons left in the glial compartment may drive the transport of lactate outside
of astrocytes and into neurons through MCTs. Excess H
+ in neurons is extruded via sodium-hydrogen exchange (NHE). Orange box: K
+ buffer-
ing. Astrocytes buffer excess K
+ released into the extracellular space as a result of neuronal activity. Potassium ions travel through the astro-
cytic syncitium down their concentration gradient and are released in sites of lower concentration. Green box: Glutathione metabolism.
Astrocytes release glutathione (GSH) in the extracellular space where it is cleaved by the astrocytic ectoenzyme γ-glutamyl transpeptidase (γGT).
The resulting CysGly serves as a precursor for neuronal GSH synthesis. X represents an acceptor for the γ-glutamyl moiety in the reaction cat-
alyzed by γGT.
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taining the overall extracellular K
+ concentration within
the physiological range. In addition to spatial buffering,
other mechanisms such as the transient storage of K
+
ions appear to contribute to the potassium-buffering
capacity of astrocytes.
32
Supply of energy substrates 
Although the brain represents only 2% of the body
weight, it is responsible for the consumption of an esti-
mated 25% of all glucose in the body.
37 This dispropor-
tionate energy need compared with other organs can be
largely explained by the energetic cost of maintaining
the steep ion gradients necessary for the transmission of
action potentials.
38 For this reason, neurons in particular
have very high energy requirements, and are therefore
highly dependent upon a tight regulation of energy sub-
strate supply in order to sustain their normal function
and cellular integrity. 
As mentioned previously, the morphological features of
astrocytes ideally position them to sense neuronal activ-
ity at the synapse and respond with the appropriate
metabolic supply via their astrocytic endfeet which
almost entirely enwrap the intracerebral blood vessels
(Figure 3). In line with this, an increasing body of evi-
dence suggests that astrocytes play a key role in the spa-
tiotemporal coupling between neuronal activity and
cerebral blood flow (known as functional hyperemia) in
a process that involves transient neurotransmitter-
induced increases of [Ca
2+]i in astrocytes, the subsequent
propagation of Ca
2+ waves through the astrocytic synci-
tium and the release of vasoactive substances (such as
arachidonic acid metabolites or ATP) by astrocytic end-
feet.
13 Importantly, the role of astrocytes in functional
hyperemia does not preclude a concerted contribution
of neurons via the release of vasoactive substances such
as neurotransmitters, nitric oxide, H
+, and K
+ to name a
few.
39
Although neurons can import glucose directly from the
extracellular space, astrocytes have been proposed to
play an instrumental role in coupling neuronal activity
and brain glucose uptake through a mechanism referred
to as the astrocyte–neuron lactate shuttle (ANLS)
(Figure 2, blue boxes).
40,41 In brief, according to the
ANLS, glutamate uptake into astrocytes following
synaptic release causes a stimulation of anaerobic gly-
colysis and glucose uptake from the circulation via
GLUT1, a glucose transporter expressed specifically by
glial and capillary endothelial cells in the brain.
42
Lactate produced by astrocytes as an end result of gly-
colysis is released into the extracellular space and taken
up by neurons via monocarboxylate transporters
(MCTs) expressed on astrocytes and neurons.
42 Once
into neurons, lactate can be used as an energy substrate
via its conversion to pyruvate by the action of lactate
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Figure 3. Astrocytic endfeet in humans. (A) Protoplasmic astrocytes
project specialized processes towards the intraparenchymal
vasculature (part of a blood vessel is highlighted in the yellow
box) (glial fibrillary acidic protein – (GFAP), white; nuclei (4',6-
diamidino-2-phenylindole - DAPI), blue. Scale bar, 20 µM). (B)
Astrocytic endfeet are in close contact with blood vessels and
almost entirely cover their surface (GFAP, white. Scale bar, 20
µM).
Adapted from ref 2: Oberheim NA, Takano T, Han X, et al. Uniquely
hominid features of adult human astrocytes. J Neurosci. 2009;29:3276-
3287. Copyright © Society for Neuroscience 2009
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chondrial TCA cycle. The existence of a lactate shuttle
between astrocytes and neurons is supported by a num-
ber of experimental studies (reviewed in ref 41). For
instance, in an elegant study by Rouach and colleagues,
43
it was recently demonstrated that 2-NBDG (a fluores-
cent glucose analogue) injected into a single astrocyte
in hippocampal slices traffics through the astrocytic net-
work as a function of neuronal activity. The diffusion of
2-NBGD across the astrocytic syncitium was indeed
reduced when spontaneous neuronal activity was inhib-
ited with tetrodotoxin, whereas increasing neuronal
activity by means of epileptiform bursts or stimulation
of the Schaffer collaterals resulted in the trafficking of
2-NBDG to a larger number of astrocytes.
43 They next
went on to show that during glucose deprivation which
resulted in a 50% depression of synaptic transmission
in hippocampal slices, glucose delivery into a single
astrocyte and its subsequent (and necessary) diffusion
through the astrocytic syncitium could rescue neuronal
activity. This effect was mimicked by lactate but was
abolished in the presence of the MCT inhibitor α-
cyano-4-hydroxycinnamic acid (4-CIN), demonstrating
that glucose present in the astrocytic network is metab-
olized to lactate, transported out of astrocytes, and used
by neurons to sustain their activity.
43 Interestingly, lac-
tate has also been shown to preserve neuronal function
in experimental models of excitotoxicity,
44 posthypoxic
recovery,
45,46 cerebral ischemia,
47 and energy depriva-
tion,
48 highlighting the importance of astrocyte-derived
lactate for neuronal function and viability. 
Another key feature of astrocytes is their capacity to
store glucose in the form of glycogen. Indeed, in the
CNS glycogen is almost exclusively present in astrocytes
and virtually constitutes the only energy reserve.
37,49
Interestingly, it has recently been demonstrated that
neurons also possess the enzymatic machinery to syn-
thesize glycogen, but that it normally is tightly sup-
pressed.
50 Failure to do so results in neuronal apoptosis,
suggesting that intracellular glycogen is actually toxic to
neurons.
50 In astrocytes, glycogen can be rapidly mobi-
lized in response to neuronal activity.
51,52 The glycosyl
units resulting from glycogen breakdown are fed into the
glycolytic pathway of astrocytes, and released into the
extracellular space in the form of lactate which can be
used to face the transiently elevated energy require-
ments associated with neuronal activation.
49,52-54 Storage
of energy in the form of glycogen is also essential for the
preservation of neuronal viability in situations where
glucose becomes scarce. For example, it has been
demonstrated that brain glycogen levels are increased
following mild hypoxic preconditioning in vivo, result-
ing in significant protection from brain damage as a
result of subsequent cerebral hypoxic-ischemic injury.
55
Beyond lactate, it is of interest to note that astrocytes
may also transfer other energy substrates to neurons.
Indeed, evidence suggests that in certain conditions,
astrocytes may be able to metabolize fatty acids or
leucine to produce ketone bodies which are know to be
readily used by neurons as an energy substrate.
56-58 It has
been suggested that this pathway may also serve a neu-
roprotective purpose by scavenging nonesterified phos-
pholipids which can lead to the production of proapop-
totic sphingolipids.
58,59
pH buffering
Another instrumental function of astrocytes in support-
ing proper neuronal function is their contribution to pH
regulation of the brain microenvironment (Figure 2, yel-
low box).
60-62 Several neuronal processes are strongly
affected by relatively small shifts in pH, including energy
metabolism, membrane conductance, neuronal excitabil-
ity, synaptic transmission, and gap junction communica-
tion.
60,62 The main feature of glial cells, endowing them
with a high pH buffering capacity, is their enriched
expression of carbonic anhydrase (CA) which converts
CO2 into H
+ and HCO3
-—effectively allowing them to
act as a CO2 sink. Indeed, CA is preferentially expressed
in astrocytes and oligodendrocytes,
63,64 although low
activity levels are also observed in neurons and in the
extracellular space.
62A coupling mechanism which inte-
grates synaptic transmission, pH regulation, and energy
supply between neurons and glia has been proposed by
J. W. Deiter.
61,65 According to this model, during periods
of high neuronal activity, the CO2 produced by elevated
(mostly neuronal) oxidative metabolism diffuses into
glial cells and is converted to H
+ and HCO3
- by the
action of glial CA. Two HCO3
- can then be transported
into the extracellular space along with one Na
+ via the
Na
+- HCO3
- cotransporter (NBC), thereby increasing the
extracellular buffering power. The protons left in the
glial compartment could be used to drive the transport
of lactate outside of astrocytes through MCT-1 and -4
and its subsequent transport by MCT-2 into neurons,
since MCTs exploit proton gradients for the transport of
Translational research
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41,61 As previously discussed, according to the
ANLS hypothesis, this lactate can then be used as an
energy substrate by neurons.
40,41 Alternatively, protons
released into the extracellular space may also be recon-
verted to CO2 and water by the action of extracellular
CA at the expense of one HCO3
-.
61 This model suggests
that pH buffering taking place in glial cells during neu-
ronal activation may also act cooperatively to: i) con-
tribute, via the Na
+- HCO3
- cotransporter, to the extru-
sion against its concentration gradient of the excess
intracellular Na
+ resulting from glutamate uptake in
astrocytes, thereby alleviating the metabolic burden on
the glial Na
+/K
+ ATPase; and ii) drive the efflux of lac-
tate which is produced in response to glutamate uptake
in astrocytes, thus providing an energy substrate for the
neuronal TCA cycle.
61,65
Defense against oxidative stress 
Oxidative stress occurs as a result of an imbalance
between the production of reactive oxygen species
(ROS) and antioxidant processes. It is known to be
involved in a number of neuropathological conditions,
including neurodegenerative diseases, traumatic brain
injury, and stroke,
66 suggesting that the CNS is particu-
larly vulnerable to oxidative injury. This can be explained
by the brain’s high rate of oxidative energy metabolism
(which inevitably generates ROS), combined with a rel-
atively low intrinsic antioxidant capacity.
67 Compared
with neurons, astrocytes display a much more effective
artillery against ROS. Accordingly, cooperative astro-
cyte-neuron defense mechanisms against oxidative stress
seem to be essential for neuronal viability.
68 This is sup-
ported by a number of studies demonstrating that when
cultured in the presence of astrocytes, neurons show
increased resistance to toxic doses of nitric oxide,
69,70
hydrogen peroxide,
71-73 superoxide anion combined with
nitric oxide,
69,74 or iron.
69,74
This neuroprotective capacity of astrocytes may derive
from the fact that they possess significantly higher lev-
els of a variety of antioxidant molecules (including glu-
tathione, ascorbate, and vitamin E) and display greater
activities for ROS-detoxifying enzymes (including glu-
tathione S-transferase, glutathione peroxidase, and
catalase).
68,72,75-78 In addition, it appears that astrocytes
may also play an active role in preventing the gener-
ation of free radicals by redox active metals, as they
participate in metal sequestration in the brain.
79This is
achieved in part through their high expression levels
of metallothioneins and ceruloplasmin, which are
involved in metal binding and iron trafficking, respec-
tively.
80-82
Glutathione (GSH) is the most important antioxidant
molecule found in the brain.
83This thiol compound can
act as an electron donor, and thus fulfills its antioxi-
dant role either by directly reacting with ROS or by
acting as a substrate for glutathione S-transferase or
glutathione peroxidase. Both neurons and astrocytes
can synthesize the GSH tripeptide (L-glutamyl-L-
cysteinylglycine) by the sequential action of glutamate
cysteine ligase and glutathione synthetase. However,
neurons are highly dependent on astrocytes for their
own GSH synthesis, as illustrated by the fact that GSH
levels are higher in neurons when they are cultured in
the presence of astrocytes.
84Astrocytes release GSH in
the extracellular space, where it is cleaved by the astro-
cytic ectoenzyme γ-glutamyl transpeptidase (γGT) to
produce CysGly, which can then be taken up by neu-
rons directly or after undergoing further cleavage by
extracellular neuronal aminopeptidase N to form
glycine and cysteine.
83 This shuttling of GSH between
astrocytes and neurons is essential in providing pre-
cursors for neuronal GSH synthesis (Figure 2, green
box). This is especially true for cysteine, the rate-lim-
iting substrate for GSH synthesis, since neurons, unlike
astrocytes, cannot use the cysteine-oxidation product
cystine as a precursor.
83 The importance of this coop-
erative process for neuronal defense against oxidative
stress is evidenced by the reduced ability of GSH-
depleted astrocytes to protect neurons against oxida-
tive injury.
85,86 Conversely, increasing the capacity to
synthesize GSH specifically in astrocytes by increasing
their capacity to uptake cystine significantly enhances
the neuroprotective effect of astrocytes against oxida-
tive stress.
87
The recycling of ascorbate is another example of coop-
eration between astrocytes and neurons for antioxidant
defense. Ascorbate can directly scavenge ROS, and is
also an important cofactor for the recycling of oxidized
vitamin E and GSH.
68Astrocytes are responsible for the
uptake of the oxidation product of ascorbate, dehy-
droascorbic acid, from the extracellular space and its
recycling back to ascorbic acid. The latter can then either
be used intracellularly in astrocytes, or released into the
extracellular space to be utilized by neurons for their
own antioxidant defense.
68
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a fine balance
Considering the extensive functional cooperativity that
exists between neurons and astrocytes, one can expect
that alterations of astrocytic pathways in response to
pathological stimuli will result in (or at least contribute
to) neuronal dysfunction. Interestingly, several neurolog-
ical diseases share common pathogenic processes, such as
oxidative stress, excitotoxicity, metabolic failure, or inflam-
mation—many of which are known to be counteracted by
the function of astrocytes in the normal brain (see previ-
ous sections). This may reflect a common underlying phe-
nomenon by which disease progression is associated with
chronic and/or escalating harmful stimuli that eventually
exhaust the neuroprotective mechanisms of astrocytes.
Even worse, deleterious pathways may then be turned on
in astrocytes, directly contributing to the pathogenic
process. A role of astrocytes has been described in a num-
ber of brain pathologies, and a complete review is beyond
the scope of this article (see refs 88-90). Instead, we focus
on three pathological processes that well illustrate the
dual role of astrocytes in neuroprotection and neurotox-
icity, namely neuroinflammation, Alzheimer’s disease, and
hepatic encephalopathy. 
Neuroinflammation
The brain can mount an immune response as a result of
various insults such as infection, injury, cellular debris, or
abnormal protein aggregates. In most cases, it constitutes
a beneficial process aiming to protect the brain from
potentially deleterious threats. In some situations, how-
ever, the insult may persist and/or the inflammatory
process may get out of control. Chronic neuroinflam-
mation sets in as a result, and may negatively affect neu-
ronal function and viability, thus contributing to disease
progression. Neuroinflammation has indeed been impli-
cated in several neuropathologies including Alzheimer’s
disease, Parkinson’s disease, amyotrophic lateral sclero-
sis, multiple sclerosis, and stroke.
91
While microglial cells are generally considered the main
resident immune cells of the brain, it is important to note
that astrocytes are immunocompetent cells as well, and
that they act as important regulators of brain inflamma-
tion. Like microglia, astrocytes can become activated—
a process known as astrogliosis, which is characterized
by altered gene expression, hypertrophy, and prolifera-
tion.
92 Activated astrocytes can release a wide array of
immune mediators such as cytokines, chemokines, and
growth factors, that may exert either neuroprotective or
neurotoxic effects.
93 Additionally, activated astrocytes
can release potentially deleterious ROS and form a glial
scar which may impede axon regeneration and neurite
outgrowth.
94 This has led to considerable debate as to
whether activation of astrocytes is beneficial or detri-
mental to neighbouring neurons. The most likely answer
is that it is neither exclusively one nor the other, and that
the overall consequences of an immune activation of
astrocytes is the result of a complex interplay between
pro- and anti-inflammatory—as well as neurotoxic and
neurotrophic—processes. 
Cytokines, for instance, are major effectors in this fine
balance as they exert a dual role, potentially sustaining
or suppressing neuroinflammation (hence their tradi-
tional labeling as pro- or anti-inflammatory). In this
regard, dissecting out the exact neuroprotective and neu-
rotoxic contributions of astrocytes in neuroinflammatory
processes has proven to be extremely challenging
because they are capable of releasing such an extensive
repertoire of cytokines in response to various stimuli
(some examples include interleukin (IL)-1β, TNFα, IL-
6, IL-10, IL-15, INFβ, and TGFβ).
93Adding another level
of complexity, astrocytes express several cytokine recep-
tors and can therefore also be a target of cytokine sig-
naling through autocrine or paracrine mechanisms.
11
While cytokines are categorized as proinflammatory or
anti-inflammatory, understanding their exact individual
effect is far more complex, as many of them interact with
each other (either antagonistically or synergistically) and
may additionally have pleiotropic effects.
11,95As a result,
cytokines can potentially mediate both neuroprotective
and neurotoxic processes at once. For example, ample
evidence indicates that IL-1β may exacerbate neuronal
injury both in vivo and in vitro.
96-99 In contrast, IL-1β has
also been implicated in neuroprotective processes such
as remyelination,
100 blood-brain barrier repair,
101 ischemic
tolerance,
102 and neurotrophic factor production.
103-106
Importantly, astrocytes can themselves respond to IL-1β
by releasing a number of potentially neuroprotective
trophic factors such as nerve growth factor (NGF), cil-
iary neurotrophic factor (CNTF), glial cell-line derived
neurotrophic factor GDNF, and fibroblast growth factor
(FGF)-2.
11,107-109
Taken together, studies such as those mentioned above
provide important information about the multiple
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major limitations, in that they can only take into account
a few pro- and anti-inflammatory pathways at a time. As
such, they may only reflect a small fraction of an infi-
nitely more intricate process in which astrocytes take
part. For this reason, the use of genetically manipulated
animal models specifically preventing the proliferation
of reactive astrocytes or the activation of their core
inflammatory pathways, has provided important new
insight into their overall role in response to brain injury.
For instance, it has been demonstrated that the selective
attenuation of astrocytic proinflammatory processes,
through genetic inactivation of the transcription factor
NF-κB specifically in this cell type, affords substantial
neuroprotection following spinal cord injury.
110 By con-
trast, using a transgenic mouse model in which dividing
reactive astrocytes were selectively ablated, Sofroniew
and colleagues have demonstrated that following vari-
ous types of brain injury, reactive astrocytes play an
essential role in temporally and spatially restricting neu-
roinflammation, as well as in promoting blood-brain bar-
rier repair, limiting brain edema, and preserving neu-
ronal viability.
94,111-113
Consistent with a role of astrocytes in containing neu-
roinflammation, it is interesting to note that astrocytes
appear to participate in the suppression of microglial
activation through negative feedback loops. Activated
microglial cells release high levels of proinflammatory
cytokines and toxic ROS which may negatively impact
neuronal survival.
114 Several in vitro studies have demon-
strated that astrocyte-conditioned medium or the pres-
ence of astrocytes attenuates microglial activation in
response to various proinflammatory stimuli.
115-117 The
exact nature of the astrocyte-derived factors involved
has not been fully elucidated, but transforming growth
factor (TFG)β is thought to contribute to this process.
115
This may in part explain the neuroprotective effect of
TGFβ in experimental models of excitotoxicity or
ischemia.
118-120
To summarize, if inflammatory activation of astrocytes
unquestionably has consequences for neuronal function
and viability, it must be emphasized that the overall
effect is dependent on the fine balance between a num-
ber of factors including the type, duration, and severity
of the insult, the complex interplay between the various
cytokines released by astrocytes and surrounding cells,
and the receptors for cytokines and growth factors
expressed by these neighboring cells.
Alzheimer’s disease
Alzheimer’s disease (AD), the most prevalent neurode-
generative disorder, is characterized by the progressive
decline of cognitive functions including memory and
mental processing, and by disturbances in behavior and
personality.
121 Typical histopathological features of the
AD brain are amyloid-β (Aβ) plaques which may con-
tain dystrophic neurites, intracellular neurofibrillary tan-
gles, vascular amyloidosis, neuronal and synaptic loss,
and reactive gliosis. Though the exact pathophysiologi-
cal mechanisms leading to synaptic loss and the result-
ing cognitive decline have not been fully elucidated, a
central role of Aβ peptides in concert with neuroin-
flammation is generally accepted.
122 Alois Alzheimer
himself in 1910 suggested that glial cells may participate
in the pathogenesis of dementia
123; however, their exact
role is still a matter of debate, as available evidence can
argue both for neuroprotective or neurotoxic effects. 
Reactive astrocytes, like microglia, are observed in close
association with Aβ plaques in the brains of AD
patients,
124,125 and both cell types have been shown to be
capable of internalizing and degrading Aβ peptides.
126-129
This is thought to be a neuroprotective mechanism by
contributing to the clearance of Aβ from the extracellu-
lar space, thus avoiding the accumulation of toxic extra-
cellular Aβ. Several observations support an active role
of astrocytes in Aβ clearance. For example, astrocytes
surrounding plaques in autopsy material from the brain
of AD patients contain intracellular Aβ deposits.
128,130 In
addition, when exogenous astrocytes were transplanted
into the brain of Aβ plaque-bearing transgenic mice,
they migrated towards Aβ deposits and internalized Aβ-
positive material.
129 Similarly in ex vivo studies, binding,
internalization, and degradation of Aβ could be
observed when cultured astrocytes were seeded on top
of plaque-bearing sections prepared either from the
brains of AD patients or transgenic mice models of
AD.
127,129The physiological importance of Aβ clearance
by glial cells in vivo is evidenced by the increased Aβ
accumulation and premature death observed in a trans-
genic mouse model of AD when microglial activation
was impaired.
131 Interestingly, glial cell activation and
astrocytic accumulation of Aβ can be observed even pre-
ceding plaque formation,
128,132 suggesting that astrocyte
cells attempt to scavenge Aβ early in the progression of
the disease, which likely reflects an effort to limit its
extracellular deposition. 
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deposits is thought to be protective, there is also evi-
dence to suggest that microglia and astrocytes contribute
to the progression of AD. One obvious explanation is
that the physiological functions of astrocytes may be
directly affected by Aβ. For instance, in a elegant study
using fluorescence imaging microscopy in live mice bear-
ing AD-like pathology, intracellular Ca
2+ signaling was
reported to be abnormally increased in astrocytes, some-
times propagating as intracellular calcium waves.
133These
Ca
2+ transients were only observed after the mice devel-
oped senile plaques and were uncoupled from neuronal
activity, suggesting that Aβ interacts directly with the
astrocytic network.
133
The involvement of glial cells in the pathogenesis of AD
is supported by several in vitro studies demonstrating that
their interaction with Aβ impairs neuronal viability or
worsens the neurotoxic effect of Aβ.
134-138 Upon their acti-
vation by Aβ, astrocytes and microglia can release a num-
ber of inflammatory mediators which may be toxic for
surrounding neurons. Examples include proinflammatory
cytokines such as IL-1β and IL-6, and reactive oxygen and
nitrogen species (RN/ROS) such as NO and O2
-.
132,139-143
Proinflammatory cytokines have been shown to exacer-
bate the microglial response to Aβ and to enhance its neu-
rotoxic effects.
144-146 Moreover, it appears that proinflam-
matory cytokines can also increase the expression of the
amyloid precursor protein and its processing through
amyloidogenic pathways.
147-149Aβ accumulation may there-
fore establish a vicious circle whereby neuronal stress and
glial activation initiates an inflammatory response, which
in turn promotes the synthesis and accumulation of more
Aβ, thus perpetuating glial cell activation. This may in part
explain why age is the most important risk factor for
developing AD since increased neuroinflammation is
associated with normal aging.
150This enhancement of the
basal inflammatory state, together with the gradual accu-
mulation of Aβ which is also seen in the normal aging
brain, may provide the trigger necessary for this vicious
circle to set in. Because of their central role in neuroin-
flammation (see previous section), glial cells may provide
a valuable therapeutic target for the treatment of AD.
This is supported by studies testing newly identified anti-
inflammatory molecules which selectively suppress pro-
inflammatory cytokines production in glia, resulting in a
significant attenuation of synaptic dysfunction and neu-
rodegeneration and in behavioral improvements in exper-
imental models of AD.
151,152
Besides proinflammatory cytokines, RN/ROS produced
by activated astrocytes and microglia may contribute to
disease progression by inducing oxidative stress, a hall-
mark of AD.
142,153Astrocytes have been proposed to take
part in this process. For example, Aβ causes intracellular
Ca
2+ transients and stimulates the production of ROS by
NADPH oxidase in astrocytes but not in neurons.
154-156 In
mixed cultures, these effects were accompanied by
decreases in GSH levels in both astrocytes and neurons,
resulting in neuronal cell death.
154-156
Conversely, in the presence of microglia, astrocytes may
provide significant protection through the negative reg-
ulation of microglial reactivity following exposure to
Aβ.
137,157 However, this must be interpreted with caution
since, as previously discussed, increased microglial
phagocytosis associated with their activated state may
be neuroprotective. In line with this, microglial phago-
cytosis was shown to be markedly suppressed in the
presence of astrocytes, which resulted in increased per-
sistence of senile plaques when presented to microglia
in vitro.
158
In summary, the apparently conflicting roles of astro-
cytes in the progression of AD may be explained by the
coexistence of potentially protective and deleterious
pathways in activated astrocytes. As the disease pro-
gresses, the overwhelming combined effect of Aβ accu-
mulation, neuroinflammation, and oxidative stress may
tip the scales away from the neuroprotective functions
of astrocytes and towards the activation of deleterious
pathways.
Hepatic encephalopathy
Hepatic encephalopathy (HE), a neuropsychiatric syn-
drome occurring as a result of chronic or acute liver fail-
ure, is one of the first identified neurological disorders
involving astroglial dysfunction as its primary cause. In
its acute form, the symptoms of HE can progress rapidly
from altered mental status to stupor and coma, and may
cause death within days. The most important cause of
mortality in acute liver failure is brain herniation, which
occurs as a result of cytotoxic swelling of astrocytes, lead-
ing to intracranial hypertension.
159 Although HE is a
multifactorial disorder, ammonia is thought to play a
central role in its pathogenesis.
159Ammonia rapidly accu-
mulates in the blood as a result of acute liver failure and
can readily cross the blood-brain barrier. Because the
brain does not possess an effective urea cycle, it relies
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ification of ammonia.
159 As mentioned before, this is
accomplished by the enzyme glutamine synthetase (GS)
which is exclusively localized in astrocytes.
29 Ammonia
detoxification is an essential homeostatic function of
astrocytes, as excess hyperammonemia has profound
effects on various brain functions.
159 However, the astro-
cytic accumulation of osmotically active glutamine as a
result of ammonia detoxification is thought to contribute
at least in part to the swelling of astrocytes in hyperam-
monemic conditions. This is supported by the demon-
stration that inhibition of GS with methionine sulfoxide
prevents brain edema in experimental hyperammone-
mia.
160Alternatively, glutamine may also induce astro-
cytic swelling via other mechanisms, including oxidative
and nitrosative stress.
161 Interestingly, glutamine efflux
from asctrocytes through the system N transporter
appears to be negatively regulated by elevated extracel-
lular glutamine in hyperammonemic conditions.
162 Such
a mechanism may contribute to trap glutamine in astro-
cytes and promote swelling. 
In contrast with its acute form, chronic hepatic
encephalopathy, which is associated with more modest
increases in brain ammonia, does not result in overt cere-
bral edema,
163 suggesting the existence of compensatory
mechanisms taking place in astrocytes in order to prevent
excessive swelling. This is thought to be accomplished by
the release of osmolytes such as taurine and myo-inosi-
tol by astrocytes in response to glutamine accumulation.
However, it appears that when osmolyte pools are
depleted as a result of excessive hyperammonemia, for
example during acute liver failure, this protective mech-
anism is exhausted and astrocytes swell as a result. This,
together with an impaired capacity of astrocytes to fulfill
their role in ammonia detoxification, seriously compro-
mises brain function in acute liver failure. 
Conclusion
Astrocytes are known to be the most important neural
cell type for the maintenance of brain homeostasis. It is
safe to assume that, as technology advances in the years
to come, we will continue to uncover the multiple facets
of astroglia. It has already become quite clear however
that it is unrealistic to approach brain function and dys-
function from a uniquely neuronal standpoint. Because
of their involvement in such a wide range of homeosta-
tic functions, any brain insult is likely to have an impact
on astrocytes. Their capacity to adapt to these changes
weighs heavily in the fine balance between neuropro-
tection and neurotoxicity as illustrated by the three neu-
ropathological conditions discussed above. In this con-
text, understanding astrocytic function is key to
providing a better grasp of brain function in general and
how it may go awry. This may lead to the identification
of better suited therapeutic targets, as they should take
into account the multiple interactions and interdepen-
dencies between neural cell types. ❏
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El papel de la astroglía en la 
neuroprotección
Los astrocitos constituyen el principal tipo celular
neural responsable del mantenimiento de la home-
ostasis cerebral. Ellos forman áreas anatómicas alta-
mente organizadas que están interconectadas en
extensas redes. Estas características, junto con la
expresión de una gran variedad de receptores,
transportadores y canales iónicos, los favorece de
manera ideal para detectar y modular dinámica-
mente la actividad neuronal. Los astrocitos coope-
ran con las neuronas a varios niveles, incluyendo el
tránsito y reciclaje de neurotransmisores, la home-
ostasis iónica, la neuroenergética y la defensa con-
tra el estrés oxidativo. Las neuronas dependen en
forma crítica de su soporte constante, lo que le con-
fiere a los astrocitos propiedades neuroprotectoras
intrínsecas, las cuales también se discuten aquí. A la
inversa, los estímulos patogénicos pueden alterar la
función astrocítica, comprometiendo así la funcio-
nalidad y la viabilidad neuronal. Se utilizan como
ejemplos la neuroinflamación, la Enfermedad de
Alzheimer y la encefalopatía hepática para discutir
cómo los mecanismos de defensa de los astrocitos
pueden estar sobrepasados en las condiciones pato-
lógicas, lo que contribuye a la progresión hacia la
enfermedad. 
Rôle de l’astroglie dans la neuroprotection
Les astrocytes sont le principal type de cellules neu-
ronales responsables de l’entretien de l’homéostasie
cérébrale. Ils s’interconnectent en réseaux étendus,
formant des régions anatomiques très organisées.
Cette organisation qui s’accompagne de toute une
série de récepteurs, transporteurs et canaux ioniques,
les met en position idéale pour pressentir et modu-
ler de façon dynamique l’activité neuronale. Les
astrocytes coopèrent avec les neurones à différents
niveaux, dont le recyclage et la circulation des neu-
rotransmetteurs, l’homéostasie ionique, la neuro-
énergétique et la défense contre le stress oxydant.
Les neurones sont très dépendants du soutien
constant des astrocytes, ce qui donne à ces derniers
des propriétés neuroprotectrices que nous analysons
dans cet article. Á l’opposé, lorsque des stimuli
pathogènes troublent la fonction astrocytaire, la
fonctionnalité et la viabilité des neurones sont com-
promises. En prenant pour exemples la neuro-inflam-
mation, la maladie d’Alzheimer et l’encéphalopathie
hépatique, nous montrerons comment les méca-
nismes de défense astrocytaires peuvent être débor-
dés en situation pathologique, participant ainsi à la
progression de la maladie.
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